2025. Integrated Safety Analysis of Abrocitinib in 3850 Patients With Moderate-To-Severe Atopic Dermatitis: Data From More Than 9600 Patient-Years With Up to 6.5 Years of Exposure. SKIN The Journal of Cutaneous Medicine. 9, 6 (Nov. 2025), s616. DOI:https://doi.org/10.25251/n1p8w126.